We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Emv Capital Plc | LSE:EMVC | London | Ordinary Share | GB00BN4R5Q82 | ORD 5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 49.50 | 0.00 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 48.00 | 51.00 | 49.50 | 49.50 | 49.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 1.45M | -2.64M | -0.1104 | -4.85 | 11.85M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 49.50 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 09/12/2024 | 07:00 | UK RNS | EMV Capital PLC Wanda Health Fundraising |
| 05/12/2024 | 19:52 | ALNC |  EARNINGS AND TRADING: Synectics deal wins; TruFin to beat expectations |
| 05/12/2024 | 07:00 | UK RNS | EMV Capital PLC Close of Fundraising and Result of Retail Offer |
| 03/12/2024 | 13:24 | UK RNS | EMV Capital PLC Result of Subscription |
| 03/12/2024 | 07:47 | ALNC | *EMV Capital plans to raise additional GBP880,000 through subscription.. |
| 03/12/2024 | 07:05 | UK RNS | EMV Capital PLC WRAP Retail Offer |
| 03/12/2024 | 07:00 | UK RNS | EMV Capital PLC Proposed Subscription and Retail Offer; Update |
| 14/11/2024 | 15:59 | UK RNS | EMV Capital PLC Replacement RNS: PDS: Update, 3rd Quarter Results |
| 14/11/2024 | 15:23 | UK RNS | EMV Capital PLC PDS: Clinical Programs Update, 3rd Quarter Results |
| 08/10/2024 | 06:00 | UK RNS | EMV Capital PLC Director/PDMR Shareholding |
Emv Capital (EMVC) Share Charts1 Year Emv Capital Chart |
|
1 Month Emv Capital Chart |
Intraday Emv Capital Chart |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-12-10 16:51:59 | 51.00 | 19,600 | 9,996.00 | O |
| 2024-12-10 16:13:02 | 49.90 | 4,809 | 2,399.69 | O |
| 2024-12-10 15:16:04 | 48.30 | 5,000 | 2,415.00 | O |
| 2024-12-10 14:30:59 | 49.90 | 600 | 299.40 | O |
| 2024-12-10 12:37:25 | 49.90 | 8,000 | 3,992.00 | O |
| Top Posts |
|---|
Posted at 11/12/2024 08:20 by Emv Capital Daily Update Emv Capital Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker EMVC. The last closing price for Emv Capital was 49.50p.Emv Capital currently has 23,945,828 shares in issue. The market capitalisation of Emv Capital is £12,811,018. Emv Capital has a price to earnings ratio (PE ratio) of -4.85. This morning EMVC shares opened at 49.50p |
Posted at 04/12/2024 16:09 by loafofbread Some of you may have seen today's FAB, Fusion antibodies RNS for grant funding that's added 50% to the share price.Good news is that ProAxis is part of the consortium so with any luck they should receive their own lump of grant funding. Let's hope they actually release the news rather than keep us in the dark! £55m shot in the arm for precision medicine in Northern Ireland Economy Minister Conor Murphy, Wendy Moore, director of data analytics at Diaceutics plc and Professor Sir Ian Greer, vice chancellor, Queen’s University, Belfast Today at 12:12 Precision medicine in Northern Ireland has received a £55m shot in the arm thanks to a joint effort from industry and academia. Economy Minister Conor Murphy launched the Future Medicines Institute (FMI) at Queen’s University on Wednesday. It’s backed by £35m from the NI Executive and £20m from NI companies in diagnostics and therapeutics. The FMI is aimed at driving innovation and production in precision medicine, with the backing of Diaceutics plc, Fusion Antibodies plc, Randox Laboratories, Almac Group, Sonrai Analytics, Exploristics and ProAxsis. Precision medicine is a branch of healthcare which tailors treatment and drugs to the specific needs of a patient. Mr Murphy said: “This £55m investment in the FMI is a landmark step for precision medicine in the north which will strengthen our life and health sciences sector and reinforce the region’s role in global healthcare innovation. “FMI will foster collaboration across industry, academia, and healthcare to accelerate the development of new drugs and diagnostics, driving growth in our economy. "It will provide a vital pathway to speed up patient access to personalised treatments, streamline drug development processes, and bring innovative solutions to market at pace.” The £55m is to be used to fund research and development between companies and universities, and to create a shared lab inside Queen’s. |
Posted at 04/12/2024 11:55 by kingston78 Investors will take up the Retail Share Offer at 50 p because the market price now stays above it. It is rarely wrong to follow the directors who put money where their mouth is. I have observed the pattern of share movement regularly, and I would say that roughly 50 p is the bottom. We should all join in to see the share price climb to 75 p in the near future.PE and institutional investors will directly invest in the company's portfolio companies. One or more of these start ups will have a promising future to become a star. |
Posted at 04/12/2024 02:28 by ohisay Just a reminder (to me!)Assuming full subscription of both the retail offer and subscription, EMV will have 27.36mn shares in issue, implying the directly held portfolio is worth around 152p per share, or more than three times the current share price. |
Posted at 03/12/2024 13:54 by kingston78 The directors are putting money where their mouth is, so I am following suit to top up my holdings at this attractive level. I have been disappointed previously because of the poor performance of the share price, and I am sitting on a paper loss. Anyway, I think that the company is likely to turn a corner from here. One day when one or more of its investments become a giant in their field, generating huge return to EMV (and us as shareholders). |
Posted at 03/12/2024 13:25 by sev22 A share offer that's hard to refuse.Venture capital and fund firm’s offer to retail shareholders is well worth participating in. Published on December 3, 2024 by Simon Thompson *£1.5mn subscription and retail offer *Wanda Health investment generates 2,077 per cent capital return in only six months *£41mn directly held portfolio *£65.7mn managed and third-party funds under management *68 per cent share price discount to proforma value of portfolio post equity raise Aim-traded investment and fund management company EMV Capital (EMVC:49p), formerly Netscientific, is raising £1.5mn through a subscription and retail offer of new shares at 50p. Specialising in the deep tech and life sciences sectors, EMV aims to deliver shareholder value by identifying and investing in companies with transformative technologies both within the UK and internationally. The strategy focuses on achieving capital returns through the profitable exits of selected portfolio companies, as well as generating carried interest from a growing funds practice, which surpassed £100mn of assets under management in the first half of 2024. The growth in the fair value of EMV’s directly held holdings has been notable since I included the shares in my 2023 Bargain Share Portfolio. In particular, a cohort of four portfolio companies in which EMV invested £0.4mn of cash and £0.4mn of in-kind services are now worth £7.1mn. They account for almost a fifth of the £38.5mn valuation of EMV’s directly held unquoted investment portfolio. The hefty revaluations reflect the read through valuations when unlisted portfolio companies raise new capital. For instance, EMV’s 21.1 per cent stake in one of the four investee companies, plastic recycling technology business DeepTech Recycling, has been valued at £1.8mn following a syndicated fundraising round led by EMV. DeepTech offers an innovative solution to the environmental challenges of plastic pollution. Other investee companies set for large revaluations. In addition, EMV’s management revealed in the fundraising document that portfolio company, Wanda Health, is expected to complete a £1mn equity funding round on 6 December 2024 at a pre-money valuation of £5mn. In May 2024, EMV acquired a 30 per cent stake in the company for £62,000, which was paid for by in-kind services. Wanda Health has commercialised an intelligent platform for remote patient monitoring and virtual care. It collects data from patients' homes or community settings, and provides it to clinicians, highlighting high risks cohorts. Effectively, the platform provides healthcare providers with data to detect exacerbations early in patients with acute, chronic, and specialty diseases, helping them speed up interventions, prevent adverse events, and improve patient adherence. EMV’s fully diluted 22.5 per cent stake in Wanda Health will have a read through valuation of £1.35mn post this week’s funding round, representing almost a 22 times increase on its investment in only six months. Sensible use of EMV’s fundraise. The proceeds of EMV’s equity raise will be used for working capital, to develop the infrastructure of the company’s wholly owned corporate finance and venture capital firm in response to growth in the syndicated investor base, and to provide ‘dry powder’ for capital investments. That’s sensible given the valuation creation the approach is now delivering. EMV’s subscription offer is raising £0.88mn at 50p per share through a bookbuild process and the WRAP retail offer aims to raise £0.62mn from existing retail shareholders at the same price through participating financial intermediaries. The retail offer closes at 4.30pm on 4 December 2024, so you have a short timeframe to participate. It’s worth doing so given the undervaluation of EMV. To put this into perspective, the last reported £41mn director valuation of the directly held (quoted and unquoted) portfolio is more than three times the company’s market capitalisation of £12mn (49p). The portfolio valuation excludes the post period end £1.3mn uplift on the Wanda Health equity stake, half of which will be offset by the second half decline in the market value (from £2.5mn to £1.8mn) of EMV’s shareholding in Nasdaq-listed PDS Biotechnology Corporation (US:PDSB), a clinical-stage company that is developing cancer immunotherapies and infectious disease vaccines. Assuming full subscription of both the retail offer and subscription, EMV will have 27.36mn shares in issue, implying the directly held portfolio is worth around 152p per share, or more than three times the current share price. So, having outlined a strong investment case when I last suggested buying the shares, at 51.5p (‘A venture capital company on a huge discount’, 1 October 2024), I would recommend participating in the retail offer. BUY. |
Posted at 16/10/2024 08:25 by 1gw Just trying to get a conversation going loaf. I looked at the interims for the values in my previous post, but there's more detail in the full-year results (prelims):£371k End-2021 £415k End-2022 £333k End-2023 based on Series C raise So we might presume that there will be a fresh valuation at end-year based on the implied equity value in the Series D raise just announced. This was from the 2023 prelims: "CytoVale Inc., (1.0% stake) remains privately held, and fair value has been established using the share price and company valuation from investments by third parties during November 2023 as part of an $84m Series C equity round that raised fresh cash of $53m and conversion of outstanding convertible notes. Fair value at year end was £333k (2022: £415k). This last observable price has been used to value the CytoVale equity investment at year end." And this from 2022 prelims: "CytoVale Inc., (1.0% stake) remains privately held, and fair value has been established using the share price and company valuation from investments by third parties during December 2019. CytoVale raised $15.0m all at the same price per share from VC, private investor and government sources. At the time this was the only observable valuation on which to value CytoVale. Fair value at year end was £415k (2021: £371k). This last observable price has been used to value the CytoVale equity investment at year end." |
Posted at 15/10/2024 19:32 by 1gw The sepsis test sounds very interesting. It's very difficult though to work out what new funding rounds mean for EMVC's interest because we don't know what rights come with the various funding rounds - do we?EMVC's stake was valued at £0.4m in the 2022 interims and the 2023 interims, vs the £0.3m in the latest interims. So it appears the value has gone down, at least before the Series D round. If you look at funding rounds, it appears they went as follows: $4.3m Series A 2014 (EMVC participated) $7.25m Series B 2017 $84m Series C November 2023 $100m Series D October 2024 So if EMVC's 1% equity, which was quoted in the 2022 interims (i.e. as of 30th June 2022), has remained unchanged up to the latest interims as of 30th June 2024 (i.e. after Series C), while the value appears to have gone down after the Series C raise then what have investors got who participated in the much bigger Series C and now Series D rounds? Have they got some sort of preferred equity, or warrants, or anti-dilution rights in future raises which EMVC doesn't have? i.e. is EMVC's "1%" likely to be materially diluted through rights held by Series C and D investors (maybe even Series B) if it ever gets to IPO or sale? |
Posted at 05/10/2024 10:27 by 1gw They also do appear to have had to resort to "internal" financing of the recent Q-Bot fundraising where they contributed a material amount of the £1.5m raised by issuing new shares (albeit at a premium) and converting fees due into Q-Bot shares.The issuing of new shares to Q-Bot is interesting, given presumably Q-Bot needs cash rather than shares. There appears to be a weak "orderly market" provision in that Q-Bot has to sell the shares through the EMVC broker, but we might guess that those shares are going to create a bit of an overhang. "The Group has participated directly in the Fundraising, including: · a £349,968.22 subscription for Q-Bot shares, such amount to settled by the Company issuing to Q-Bot 411,727 new ordinary shares in the capital of the Company (Consideration Shares) at a price of £0.85 per New Share, a 35.0 per cent. premium to the closing price of the Company's ordinary shares on 29 July 2024; and · a £198,143.92 advance subscription pursuant to an ASA, converting outstanding fees due to EMV Capital into Q-Bot shares. EMV Capital's EMVC Evergreen EIS Fund has also participated in the ASA. The Consideration Shares are subject to orderly market provisions such that if they are to be disposed of they must be sold through the Company's broker." |
Posted at 05/10/2024 10:13 by 1gw I think the balance sheet and going concern statements are a matter of legitimate concern, and are one of the key things that has held me back so far from investing here.While there appear to be plenty of options to raise cash, the fact is that the near term funding requirements have increased between end-2022 and end-2023 and they have not so far managed to achieve a portfolio exit that would provide them with a decent cash buffer. Compare these sections of the going concern statement from 2022 and 2023 full year results. Note that the amount required in the near-term (broadly 1 year beyond publication of the full year results in May/June) has gone up from £1.5m to £3.6m, although it looks like the 2022 number excludes the subsidiary companies whereas for 2023 they've brought subsidiary financing into scope. Note also that in the 2023 statement they have dropped the comment about having "no current intention to pursue [a placement] in light of the Company's current share price relative to its net assets." 2022: "For the period to June 2024, the Group requires a minimum of approximately £1.5 million to continue as a going concern, assuming that its subsidiary portfolio companies continue to be fully funded by external financing as expected. This amount can be financed through several options, either on their own or in combination, including accelerating revenues at Group level, partial or full exits from portfolio company stakes, soft and non-dilutive finance, and/or a placement of NetScientific shares. Whilst a placement of NetScientific shares remains an available option, the Board has no current intention to pursue that in light of the Company's current share price relative to its net assets." 2023: "For the period to June 2025, the Group requires (including subsidiaries) a minimum of approximately £3.6 million to continue as a going concern. NetScientific and EMV Capital require £1.6m, while the other subsidiary portfolio companies Glycotest, ProAxsis and Cetromed require £2.0 million. This amount can be financed through several options, either on their own or in combination. The subsidiary companies plan to be funded by external financing, as they have done in 2023. This could include convertible loans, equity or debt finance. The Board's plans for satisfying the going concern needs of NetScientific and EMV Capital are primarily based on service fees for corporate finance, value creation services, fund management and other fees. The Board plans to sell various portfolio assets in part or in full in order to meet the funding requirements. The Board can also consider the option of a placement of NetScientific shares." |
Posted at 02/10/2024 06:46 by sev22 A venture capital company on a huge discount.Shares trade on a near-70 per cent discount and you're getting its carried interests thrown in for free. Published on October 1, 2024 by Simon Thompson *Assets under management up 44 per cent to £106.7mn *£41mn director fair valuation of direct holdings *Managed and third-party holdings up 71 per cent to £65.7mn Aim-traded investment and fund management company EMV Capital (EMVC:51.5p), formerly Netscientific, has expanded its portfolio to more than 70 companies and increased total AUM above £100mn for the first time in its history. In May 2024, the deeptech and life sciences venture capital group was appointed as investment manager to Cambridge-based Martlet Capital, an early-stage venture capital fund that has a £24.1mn portfolio of unquoted investments. EMV is managing the funds on a discretionary basis and will earn annual recurring investment management fees of more than £0.5mn for a minimum of four years as well as earning carried interest fees based on the increase in fair value of each portfolio company. The addition of Martlet accounted for three-quarters of the £32.7mn rise in the group’s AUM in the first half, the other contributing factor being an increase in the directors’ fair valuation of EMV’s directly held unquoted investment portfolio from £31.1mn to £38.5mn. It was driven mainly by gains on two investee companies: DeepTech Recycling, a plastic recycling technology business offering an innovative solution to the environmental challenges of plastic pollution; and ProAxsis, a respiratory diagnostics company and a spin-out from Queens University Belfast. The carrying valuation of investee company DeepTech accounted for £1.8mn of the portfolio increase after EMV led a £2.1mn syndicated fundraising that increased the value of the company’s 21.2 per cent equity stake to £1.8mn. The gain was even larger on EMV’s holding in ProAxsis after the company closed a £1.8mn investment round led by EMV at a read-through valuation that more than doubled the value of the group’s 88 per cent stake to £8mn. Deep discount to fair valuation. It’s only fair to point out that investors continue to take a cautious approach to the directors’ fair valuations, that small-cap investment companies are out of favour and that EMV reported a first-half pre-tax loss of £0.6mn on its core activities. However, the undervaluation of EMV is extreme as its market capitalisation of £12.5mn (51.5p) is almost 70 per cent less than the £41mn (171p) director valuation of the directly held portfolio. That seems incredibly harsh given that several investee companies have been raising capital at read-through valuations that fully support the directors’ valuations. Moreover, EMV has significant carried interests on third-party fund holdings, albeit these are difficult to value and will take time to realise. EMV also holds a 3 per cent stake currently worth £3.1mn (£2.5mn in interim accounts) in Nasdaq-listed PDS Biotechnology Corporation (US:PDSB), a clinical-stage company that is developing cancer immunotherapies and infectious disease vaccines, which could be readily realised. So, having suggested buying the shares at 64p in my 2023 Bargain Share Portfolio, I can see potential for divestments and exits from several investee companies to narrow EMV’s share price discount in more benign market conditions for microcap companies. RECOVERY BUY. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
